Briggs Morrison’s Crossbow unveils $77M Series B for T cell engagersnews2026-03-18T13:02:40+00:00March 18th, 2026|Endpoints News|
Shanghai biotech Excalipoint gains $68.7M for T cell engagersnews2026-03-18T12:00:09+00:00March 18th, 2026|Endpoints News|
New renal disease biotech R1 Therapeutics nabs $77.5M for Phase 2bnews2026-03-17T11:00:34+00:00March 17th, 2026|Endpoints News|
J&J pulls out of NYC biotech incubator as it shrinks locationsnews2026-03-17T11:00:29+00:00March 17th, 2026|Endpoints News|
After Novartis pact, macrocycle shop Unnatural Products gets $45M Series Bnews2026-03-16T11:00:17+00:00March 16th, 2026|Endpoints News|
Gubra plots Roivant-like model as partnered obesity drugs take flightnews2026-03-13T15:21:57+00:00March 13th, 2026|Endpoints News|
Pfizer to close Ignite, its R&D services unit for small biotechsnews2026-03-12T16:22:55+00:00March 12th, 2026|Endpoints News|
Biotech startups use funding extensions to sidestep full capital roundsnews2026-03-12T15:20:55+00:00March 12th, 2026|Endpoints News|
RA Capital, Forbion and Canaan appear to back Harbour’s CTLA-4 partner Solsticenews2026-03-11T11:00:40+00:00March 11th, 2026|Endpoints News|
Breakout Ventures closes $114M fund, plans 20 investmentsnews2026-03-10T11:00:55+00:00March 10th, 2026|Endpoints News|
